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studies providing a breakdown on direct costs, the largest pro-
portion of direct medical costs for low back pain was spent on
physical therapy (17%) and inpatient services (17%), followed
by pharmacy (13%) and primary care (13%). Among studies
providing estimates of total costs, indirect costs due to lost work
productivity represented a majority of overall costs associated
with low back pain. Three studies reported that estimates with
the friction period approach were 56% lower than with the
human capital approach. CONCLUSION: Estimates of the eco-
nomic costs in different countries vary greatly depending on
study methodology but by any standards must be considered a
substantial burden on society. This review did not identify any
studies estimating the total costs of low back pain in the US from
a societal perspective. Such studies may be helpful in determining
appropriate allocation of health care resources devoted to this
condition.
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OBJECTIVE: This study quantiﬁes the direct and indirect costs
of obesity within a cohort of commercially-insured employees
between 2003–2005. METHODS: A database of health plan
claims, self-reported health risk assessments (HRAs), and pro-
ductivity data (Thomson MarketScan) from 2003–2005 was
used to identify individuals for analysis. The study cohort
included individuals reporting a valid body mass index (BMI)
value on an HRA and 12 months of continuous eligibility.
Patients were divided into ﬁve groups according to the WHO
classiﬁcation of BMI: severely obese (BMI  35), obese
(30  BMI < 35), overweight (25  BMI < 30), normal weight
(18.5  BMI < 25), and underweight (BMI < 18.5). Mean direct
medical costs and the costs associated with employee absence
were calculated for each BMI group. Two-part regression models
were used to estimate the incremental direct and indirect costs,
conditional upon expenditure, associated with elevated BMI.
RESULTS: Of 88,984 employees (45% female, mean
age = 42.3), 9.9% were severely obese, 16.7% obese, 38.5%
overweight, 34.0% normal weight, and <1% were underweight.
With the exception of the underweight BMI group, univariate
analysis reveals a graded pattern of expenditures for emergency
room and outpatient pharmacy. As BMI increases, expenditures
for these services increase. Further, compared to those with a
normal BMI, the obese and severely obese have higher costs for
inpatient hospital and outpatient visits and services. Regression-
adjusted incremental direct medical costs associated with being
overweight, obese, and severely obese were estimated to be
$147.11, $712.34, and $1977.43, respectively. Regression-
adjusted incremental indirect costs due to paid time off associ-
ated with being overweight, obese, and severely obese were
estimated at $1403.81 $1511.24, and $1414.09, respectively.
CONCLUSION: Overall health care costs were higher for
workers who were obese or severely obese than for those of
normal weight or who were overweight. Indirect costs incurred
from paid time off were higher for workers in all categories of
elevated BMI relative to those of normal weight.
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OBJECTIVE: To evaluate the cost and outcomes of a weight
control program in a regional hospital at southern Taiwan.
METHODS: A total of 249 subjects with BMI over 24 were
recruited from August 2003 to June 2004. Monthly courses
providing nutritional consultation and exercise instructions for
ﬁtness were offered in three sessions per week with class size less
than 25 members. Content of the course includes Physical Fitness
exercise coaching, healthy diet and prescription of medication for
weight control, and consultation for behavior change. Statistic
analysis of data was performed with SAS software. RESULTS:
The mean age of the 249 subjects is 38.39(12.36) years old,
with 202(81.1%) female and 47(19.9%) male. The mean of BMI
is 29.98(5.10) kg/m2, mean of body fat percentage is
38.88(7.54). Cost for the weight control clinic service includes
pharmaceutical, special formula of diet, education for healthy
eating, aerobic exercise coaching, personnel and administrative
expense. Analysis revealed the total cost for each person-visit of
a subject is 4426 NT dollars, with 5016 NT dollars per visit for
subjects accepting additional ﬁtness training. The weight
decrease in average is 4.52 + 7.52 kg, and the length of follow up
in average is 68.97 + 54.36 day. In total there is 610.3 kg
of weight reduction during the period of the project and the
average cost for each kg weight reduction is 2212  516 NT
dollars. Statistic analysis with Mixed Model revealed that after
adjusted by gender and age, the BMI of subjects will decrease by
an estimate of 0.03757 with the increase of each day. CONCLU-
SION: The strategy of combining medication prescription, diet
consultation and exercise coaching to reduce body weight in the
beginning of the course is an effective enforcement to motivate
the subject to establish the habit of regular exercise.
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OBJECTIVE: Among hospitalized patients, hyponatremia
(serum sodium <136 mmol/L) is a common problem associated
with increased mortality, morbidity, and length-of-stay (LOS)
in clinical trials and other studies. However, studies relating
hyponatremia to costs, controlling for the other factors, are
limited. The purpose of this study was to examine the relation-
ships between hyponatremia and hospital mortality, LOS, and
costs in naturalistic settings with large sample size. METHODS:
We conducted a retrospective analysis of nationally projected
adult acute care inpatient discharges from January 2003–June
2006, in the Premier Perspective clinical and economic database
of >37 million actual discharges from ~600 US hospitals. We
compared patients with hyponatremia (ICD-9-CM diagnosis
code 276.1x) during hospitalization to a comparably sized
random sample without hyponatremia, matched on age, gender,
and comorbidities. Descriptive analyses including APR-DRG
severity-of-illness, mortality, LOS, and costs. Chi-squared tests
were used for mortality comparisons and Kruskal-Wallis for LOS
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and cost comparisons, with alpha = 0.05. Multivariate regression
analyses adjusted for potential cofactors inﬂuencing descriptive
analyses: logistic for mortality, negative binomial for LOS, and
log-linear for costs. RESULTS: Severity of illness was severe/
extreme for 60.2% of 2,989,776 projected hyponatremia
patients compared to 39.7% of 2,994,724 matched non-
hyponatremia patients. Mortality among hyponatremia patients
was greater than among non-hyponatremia patients (6.8%
versus 5.6%; p < 0.0001). On average, hyponatremia was asso-
ciated with 2.6 more hospital days (8.5  10.5 versus 5.9  7.7)
and 1.5 more ICU days (6.1  8.5 versus 4.6  6.7) than
non-hyponatremia (both p < 0.0001). Average total hospital
costs were $3254 greater for hyponatremia patients than non-
hyponatremia patients ($14,317  23,251 versus $11,064 
18,325; p < 0.0001). Multivariate analyses conﬁrmed greater
mortality (Odds ratio 1.03, p < 0.0001) and LOS among
patients with hyponatremia (p < 0.0001). CONCLUSION:
Hyponatremia is associated with greater severity of illness and
risk of mortality, longer LOS, and greater hospital costs. Cor-
recting hyponatremia may be important in improving these
outcomes.
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OBJECTIVE: To determine the Hemophilia A (HA) treatment
(pdFVIII or rFVIII) with the lowest cost per quality-adjusted
life-year (QALY) inMexico.METHODS:A cost-utility study was
conducted, with an institutional perspective, in two time horizons,
30 and 50 years. The discounting rate was three percent for costs
and beneﬁts. The source of information was ameta-analysis of the
international literature validated by Mexican hematologists using
the Delphi technique. A decision tree with Bayesian approach and
a Markov chain considering the probabilities of getting infected
with Hepatitis C Virus (HCV) and Immunodeﬁciency Virus (HIV)
because of the use of a Factor VIII concentrate and the availability
of the products were performed, we also included the probabilities
of HCV and HIV infections due to the use of cryoprecipitates
because of the lack of the treatments analysed. Themodel included
the states of health: HA without infection, HA+HCV, HA+HIV,
HA+HIV+HCV and death. Due to lack of published information
and low incidence observed, the probability of getting infected
with an emergent disease (Creutzfeld-Jakob, SARS) due to the use
of FVIII treatment was not included. The results were evaluated
with incremental analysis and net beneﬁts varying the incidence of
HIV and HCV and the availability of the products. The sensitivity
analysis was one-way, two-way and probabilistic (acceptability
curves and net beneﬁts).RESULTS: Patients using rFVIII get more
beneﬁts with the lowest cost per QALY when comparing to
pdFVIII treatment (30 years-analysis: rFVIII = 16.45 QALY and
USD$50,673/QALY, pdFVIII = 11.05 QALY and USD$51,950/
QALY, ICER USD$48,066; 50 years-analysis: rFVIII = 20.79
QALY and USD$51,406/QALY, pdFVIII = 12.23 QALY and
USD$60,765/QALY, ICER USD$38,042). The sensitivity analysis
varying the incidence of HIV and HCV showed the robustness of
the base study. CONCLUSION: Recombinant Factor VIII is a
cost-effective option in the treatment of patients with hemophilia
A in Mexico.
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OBJECTIVE: Immunoglobulin replacement is standard therapy
that prevents/controls infectious complications caused by
primary immunodeﬁciency disorders especially common vari-
able immunodeﬁciency and X-linked agammaglobulinemia. In
Canada, the therapy is administered intravenously (IVIg) at hos-
pital, whereas in some European countries it is administered
subcutaneously (SCIg) at home and intravenously at home/
hospital. Canadian Blood Service is considering establishing SCIg
as an alternative to IVIg. Concerns over increasing health care
costs raise questions about its cost-effectiveness. The present
study is intended to estimate cost effectiveness of SCIg against
hospital-IVIg and hypothetical home-IVIg from Canada’s public
health care payer perspective. METHODS: A Markov decision-
analytical model for hypothetical patients in 12-month therapy
was used to estimate the incremental cost-effectiveness ratio
(ICER) per quality-adjusted life year (QALY) for SCIg compared
with hospital-IVIg and home-IVIg. Serious adverse events, mor-
tality, number and severity of infections were considered.
RESULTS: SCIg dominates (greater beneﬁts at lesser costs)
hospital-IVIg and produces an incremental cost effectiveness
ratio (ICER) of CND$39,500/QALY when compared to home-
IVIg. ICER is sensitive to changes in utility of infection, hospital
charges, and infusion materials. CONCLUSION: SCIg appears
to be the most cost-effective intervention if decision makers are
willing to pay CND$39,500/QALY. Therefore, it could be gradu-
ally established as an alternative to patients who are willing and
clinically suitable to switch. Uncertainty in the available com-
parative clinical effectiveness warrants a reliable comparative
clinical study.
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OBJECTIVE: To assess the prevalence of metabolic syndrome
in ﬁve European countries and to quantify its impact on
resource utilization. METHODS: Data were from the 2006
European National Health and Wellness Survey (NHWS), a
self-administered, Internet-based study of the health care atti-
tudes, behaviors, disease states, and outcomes of a demographi-
cally representative sample of adults age 18+ across ﬁve
European countries: France, Germany, Italy, Spain, and UK.
Individuals were categorized with metabolic syndrome if they
were diagnosed with diabetes and had two or more of the fol-
lowing: hypertension, high cholesterol, or obesity (BMI > 30).
Prevalence estimates were computed using frequency weights
based on gender and age distribution of each country as
reported in the International Database of the U.S. Census
Bureau. Linear regression models were developed using
unweighted data to assess the association between metabolic
syndrome and resource utilization in the past six months.
Covariates included in the models included gender, age, marital
status, education, and country of residence (reference=UK).
RESULTS: There were 1092 respondents across the ﬁve Euro-
pean countries that were categorized as having metabolic syn-
drome. These respondents project to approximately 6.24
million individuals affected by metabolic syndrome. The preva-
lence of metabolic syndrome varied across the 5 countries
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